Help Get Patients to Their LDL-C and A1C Goals: Welchol® (colesevelam HCl) and the ADDvantage Program™

Published Online: Friday, June 1, 2012
This product bulletin was brought to you by Daiichi Sankyo, Inc.

This product bulletin describes the efficacy and safety of Welchol, a bile acid sequestrant. Welchol is the first and only add-on to a statin and metformin that is approved by the FDA as an adjunct to diet and exercise to lower both low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin (A1C) levels in adults with primary hyperlipidemia and type 2 diabetes mellitus. It also describes the ADDvantage Program, an innovative program to help keep patients on their LDL-C and A1C medications by enabling them to save money on multiple prescriptions and providing valuable resources and tools to help get them to their LDL-C and A1C goals.

To view the  Welchol® (colesevelam HCl) product information, please click here

To view the full product bulletin, please click here or the image below.



Related Articles
Women diagnosed with polycystic ovary syndrome are more likely to develop heart disease, diabetes, and other chronic conditions than those without the hormone disorder.
Not every patient requires an aspirin a day.
The FDA announced today that it will permit the marketing of a mobile medical app that will help patients with diabetes share data from a continuous glucose monitor with other individuals.
The introduction of sodium glucose transporter 2 inhibitors has marked a turning point in the management of patients with both type 1 and type 2 diabetes.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$